Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Medroxyprogesterone for duration of non-invasive ventilation in hospitalized COPD patients
IRCT20190810044500N21Phase 2Completed
- Sponsor
- Shahid Sadoughi University of Medical Sciences
- Start
- Feb 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Medroxyprogesterone with Placebo (2 arms). Primary endpoints: Mortality rate, Duration of ventilation and 6 more. Started Feb 2022; status: completed.
02
Drugs
medroxyprogesterone acetate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on IRCT20190810044500N21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190810044500N21.